VXRT · Vaxart, Inc. · Documents

$0.32 +0.00 (+0.00%) At close · Jul 8 Play latest call Q4 2025 earnings call transcript

Market Cap

$126.27M

243.70M

Volume · Jul 8 11.57M Avg daily vol (3M) 4.77M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $237.26M up 726.7% 10-K filed Mar 13, 2026 Quarterly report FY2026 Q3 Revenue $10.62M down 85.3% 10-Q filed Nov 5, 2026 Latest results COVID-19 trial data expected by mid-year 2027 8-K filed Nov 5, 2026 Earnings call Q4 2025 earnings call Held Mar 12, 2026

2026

Nov 5

Quarterly report 10-Q FY2026 Q3, ended Sep 30

Cash Shortfall Raises Going-Concern Doubt

Vaxart reported $65.5 million in cash, cash equivalents and short-term investments as of September 30, 2026, saying they would not fund at least 12 months of operations and raising substantial doubt about its going concern.

Revenue $10.62M ▼ 85.3% Net loss $17.69M

Read from the first part of this long document

4 source passages

Aviragen changed its name to Vaxart, Inc. (together with its subsidiaries, the “Company” or “Vaxart”) and Private Vaxart changed its name to Vaxart Biosciences, Inc. As of September 30, 2026, the Company had cash, cash equivalents and short-term investments of $65.5 million. The Company’s cash, cash equivalents and investments are not sufficient to fund the Company’s planned operations for at least the period of 12 months from the date the unaudited condensed consolidated financial statements are issued. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the date of the issuance of these unaudited condensed consolidated financial statements. Open the document at this passage

Nov 5

Current report 8-K

COVID-19 trial data expected by mid-year 2027

Vaxart expects COVID-19 trial efficacy and safety data from 400 participants and approximately 5,000 participants by mid-year 2027. Third-quarter 2026 revenue was $10.6 million, and net loss was $17.7 million.

Financial results

4 source passages

COVID-19 Program Update The Company expects to release topline efficacy and safety data from the complete study, comprising the 400 participants in the sentinel safety cohort and approximately 5,000 participants in the main cohort, by mid-year 2027. Revenue for the third quarter of 2026 was $10.6 million, compared to $72.4 million for the third quarter of 2025. Vaxart reported a net loss of $17.7 million for the third quarter of 2026, compared to a net loss of $8.1 million for the third quarter of 2025. Open the document at this passage

Oct 19

Current report 8-K Events of Oct 16

Director or officer change, or executive pay, Regulation FD disclosure

Vaxart appointed retired Navy Vice Admiral Raquel C. Bono, M.D., to its Board of Directors effective October 16, 2026, pursuant to a July 2026 stockholder cooperation agreement, where she will chair the Stockholder Engagement Committee.

Sep 14

Current report 8-K Events of Sep 3

Other events AI summary on its way

Aug 25

Current report 8-K Events of Aug 21

Other events AI summary on its way

Aug 6

Current report 8-K

Financial results AI summary on its way

Aug 6

Quarterly report 10-Q FY2026 Q2, ended Jun 30

Quarterly report for FY2026 Q2 AI summary on its way

Revenue $27.19M ▼ 31.6% Net loss $13.49M

Jul 28

Current report 8-K Events of Jul 27

Other events AI summary on its way

Jul 17

Current report 8-K Events of Jul 16

Shareholder vote results, Regulation FD disclosure AI summary on its way

Jul 7

Current report 8-K Events of Jul 6

Other events AI summary on its way

Jul 6

Proxy statement DEFA14A